KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Vikas Gupta, Stephen Oh, Timothy Devos, Viviane Dubruille, John Catalano, Tim C P Somervaille, Uwe Platzbecker, Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiri Mayer, Arpad Illes, Catherine Ellis, Zhaohui Wang, Francisco J Gonzalez Carreras, Bryan Strouse, Ruben Mesa

Leuk Lymphoma 65(7) 965-977

PMID38501751
PMCID-
DOI10.1080/10428194.2024.2328800
发表日期2024-03-19
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, we performed a descriptive post hoc exploratory analysis of the double-blind, randomized, phase 3 SIMPLIFY-1 study (NCT01969838; N = 432, JAK inhibitor naive, momelotinib vs. ruxolitinib); subgroups were defined by baseline hemoglobin: <10 (moderate/severe), ≥10 to <12 (mild), or ≥12 g/dL (nonanemic). Spleen and symptom results were generally consistent with those previously reported for the intent-to-treat population. In anemic subgroups, momelotinib was associated with higher rates of transfusion independence and reduced/stable transfusion intensity vs. ruxolitinib. No new or unexpected safety signals were identified. Overall, momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. ruxolitinib in patients with hemoglobin <12 g/dL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。